Results 31 to 40 of about 27,150 (219)

Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm

Viruses, 2023
(1) Background: Some severe COVID-19 patients develop hyperinflammatory cytokine storm syndrome (CSS). We assessed the efficacy of anakinra added to standard of care (SoC) in hospitalized COVID-19 CSS patients.
Lesley E. Jackson, Nitasha Khullar, Timothy Beukelman, Chris Chapleau, Abhishek Kamath, Randy Q. Cron, Walter Winn Chatham   +6 more
doaj   +1 more source

Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature [PDF]

, 2015
Macrophage activation syndrome (MAS) is a potentially fatal condition. It is a rare complication of several autoimmune disorders, including systemic lupus erythematosus (SLE) and systemic juvenile idiopathic arthritis (sJIA).
Didona, Dario, Feola, Aldo, Granata, Guido, Granata, Massimo, Stifano, Giuseppina   +4 more
core   +4 more sources

Schnitzler Syndrome: A Dramatic Response to Anakinra [PDF]

Dermatology and Therapy, 2016
Schnitzler syndrome is a rare acquired systemic disease with a chronic evolution and difficult treatment. We report a 50-year-old woman with Schnitzler syndrome for 10 years, with major impact on her quality of life and refractory to conventional therapies.
Manuela Micaelo, Francesca Pierdomenico, Joao Freitas, Ana Isabel Gouveia   +3 more
openaire   +2 more sources

Protective effect of anakinra on audiovestibular function in a murine model of endolymphatic hydrops

Frontiers in Cellular Neuroscience, 2022
IntroductionMénière’s disease (MD), a common disease in the inner ear, is characterized by an increase in endolymph in the cochlear duct and vestibular labyrinth. The pathophysiology of the condition appears to be the immune response.
Na Zhang, Na Zhang, Na Zhang, Na Li, Na Li, Na Li, Siyue Wang, Siyue Wang, Siyue Wang, Wandi Xu, Wandi Xu, Wandi Xu, Jiahui Liu, Jiahui Liu, Jiahui Liu, Yafeng Lyu, Yafeng Lyu, Yafeng Lyu, Xiaofei Li, Xiaofei Li, Xiaofei Li, Yongdong Song, Yongdong Song, Yongdong Song, Ligang Kong, Ligang Kong, Ligang Kong, Yalan Liu, Yalan Liu, Yalan Liu, Jia Guo, Jia Guo, Jia Guo, Zhaomin Fan, Zhaomin Fan, Zhaomin Fan, Daogong Zhang, Daogong Zhang, Daogong Zhang, Haibo Wang, Haibo Wang, Haibo Wang   +41 more
doaj   +1 more source

Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study

Frontiers in Pediatrics, 2023
BackgroundThe treatment of multisystem inflammatory syndrome in children unresponsive to first-line therapies (IVIG and/or steroids) is challenging. The effectiveness of IL-1 receptor antagonist, anakinra, is debated.Patients and methodsWe conducted an ...
Francesco Licciardi, Carlotta Covizzi, Marta Dellepiane, Nicole Olivini, Maria Vincenza Mastrolia, Andrea Lo Vecchio, Viviana Monno, Maria Tardi, Angela Mauro, Maria Alessio, Giovanni Filocamo, Marco Cattalini, Andrea Taddio, Roberta Caorsi, Gian Luigi Marseglia, Francesco La Torre, Andrea Campana, Gabriele Simonini, Angelo Ravelli, Davide Montin   +19 more
doaj   +1 more source

Molecular Predictors of Anakinra Treatment Success in Heart Failure Patients with Reduced Ejection Fraction [PDF]

, 2020
Background. Kineret (Anakinra) is an interleukin-1 antagonist that is under investigation for its novel clinical application treating patients that have heart failure with reduced (\u3c50%) ejection fraction (HFrEF).
Abbate, Antonio, Alshammari, Suad, Alsultan, Monther, Buckley, Leo F., Canada, Justin M, Carbone, Salvatore, Contaifer, Daniel, Jr, Morriss, Joshua, Price, Elvin T., Ranasinghe, Asanga D., Trankle, Cory, Van Tassell, Benjamin W., Wijesinghe, Dayanjan S, Wohlford, George   +13 more
core   +1 more source

Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition [PDF]

, 2018
Following a myocardial infarction (MI), the immune system helps to repair ischaemic damage and restore tissue integrity, but excessive inflammation has been implicated in adverse cardiac remodelling and development towards heart failure (HF).
Cleland, John G.F., Harding, Sian E., Hasham, Muneer G., Khan, Habib, Panahi, Mona, Papanikolaou, Angelos, Rosenthal, Nadia A., Sattler, Susanne, Torabi, Azam, Vazir, Ali, Zhang, Ji-Gang   +10 more
core   +2 more sources

National Institute for Clinical Excellence and its value judgments [PDF]

, 2004
The National Institute for Clinical Excellence (NICE) offers health professionals in England and Wales advice on providing NHS patients with the highest attainable standards of care.
Culyer, A.J., Rawlins, M.D.
core   +2 more sources

Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study

International Journal of Infectious Diseases, 2021
Objective: The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy.
A. Balkhair, I. Al-Zakwani, M. Al Busaidi, A. Al-Khirbash, S. Al Mubaihsi, H. BaTaher, J. Al Aghbari, I. Al Busaidi, M. Al Kindi, S. Baawain, A. Al Alawi, A. Al Lawati, B. Al Rawahi, K. Al-Baimani, K. Al Zidi, N. Elfatih, B. Dawud, B. John, F. Rehman, F. Yousif, G. Al Khadouri, I. Saber, J. Lal, M. Gargouri, M. Al-Ward, N. AbuDraz, S. Al Ruqeishi, S. Kumar, W. Abdelmottaleb, Z. Al-Naamani, Z. Bin Nazar, O. Balkhair   +31 more
doaj  

Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study

Critical Care, 2020
Background A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases.
Emma J. Kooistra, Nicole J. B. Waalders, Inge Grondman, Nico A. F. Janssen, Aline H. de Nooijer, Mihai G. Netea, Frank L. van de Veerdonk, Esther Ewalds, Johannes G. van der Hoeven, Matthijs Kox, Peter Pickkers, the RCI-COVID-19 Study Group   +11 more
doaj   +1 more source